• 1
    Devic E. Myélite aiguë compliquée de névrite optique. Bull Med (Paris). 1894; 8: 10334.
  • 2
    Mandler RN, Davis LE, Jeffery DR, Kornfeld M. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 1993; 34: 1628.
  • 3
    O'Riordan JI, Gallagher HL, Thompson AJ, Howard RS, Kingsley DP, Thompson EJ, et al. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J Neurol Neurosurg Psychiatry. 1996; 60: 3827.
  • 4
    Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology. 1999; 53: 110714.
  • 5
    Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007; 6: 80515.
  • 6
    Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet. 2004; 364: 210612.
  • 7
    Weinshenker BG, Wingerchuk DM, Nakashima I, Fujihara K, Lennon VA. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol. 2006; 5: 1101.
  • 8
    Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med. 2005; 202: 4737.
  • 9
    Albutt TC. On the ophthalmoscopic signs of spinal disease. Lancet. 1870; 98: 768.
  • 10
    Aoyama T. A case of acute myelitis and blindness. J Tokyo Med Assoc. 1891; 5: 82730.
  • 11
    Gault F. De la neuromyélite optique aiguë. Lyon. 1894 (thesis).
  • 12
    Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol. 2003; 2: 11727.
  • 13
    Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of clinical picture of multiple sclerosis, comparison between British and Japanese patients. J Neurol Sci. 1981; 49: 25371.
  • 14
    Nakashima I, Fujihara K, Takase S, Itoyama Y. Decrease in multiple sclerosis with acute transverse myelitis in Japan. Tohoku J Exp Med. 1999; 188: 8994.
  • 15
    Kira J, Yamasaki K, Horiuchi I, Ohyagi Y, Taniwaki T, Kawano Y. Changes in the clinical phenotypes of multiple sclerosis during the past 50 years in Japan. J Neurol Sci. 1999; 166: 537.
  • 16
    Osoegawa M, Kira J, Fukazawa T, Fujihara K, Kikuchi S, Matsui M, et al. Temporal changes and geographical differences in multiple sclerosis phenotypes in Japanese: nationwide survey results over 30 years. Mult Scler. 2009; 15: 15973.
  • 17
    Pittock SJ, Lennon VA, de Seze J, Vermersch P, Homburger HA, Wingerchuk DM, et al. Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol. 2008; 65: 7883.
  • 18
    McKeon A, Lennon VA, Jacob A, Matiello M, Lucchinetti CF, Kale N, et al. Coexistence of myasthenia gravis and serological markers of neurological autoimmunity in neuromyelitis optica. Muscle Nerve. 2009; 39: 8790.
  • 19
    Takahashi T, Fujihara K, Nakashima I, Misu T, Miyazawa I, Nakamura M, et al. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titer. Brain. 2007; 130: 123543.
  • 20
    Waters P, Vincent A. Detection of anti-aquaporin-4 antibodies in neuromyelitis optica: current status of the assays. Int MS J. 2008; 15: 99105.
  • 21
    Waters PJ, McKeon A, Leite MI, Rajasekharan S, Lennon VA, Villalobos A, et al. Serologic diagnosis of NMO: a multicente comparison of aquaporin-4-IgG assays. Neurology. 2012; 78: 66571.
  • 22
    Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, et al. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain. 2008; 131: 307280.
  • 23
    Weinshenker BG, Wingerchuk DM, Vukusic S, Linbo L, Pittock SJ, Lucchinetti CF, et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol. 2006; 59: 5669.
  • 24
    McKeon A, Pittock SJ, Lennon VA. CSF complements serum for evaluating paraneoplastic antibodies and NMO-IgG. Neurology. 2011; 76: 110810.
  • 25
    Miyazawa I, Fujihara K, Itoyama Y. Neuromyelitis optica (Devic disease) and optic-spinal form multiple sclerosis. No To Shinkei (Brain and Nerve). 2001; 53: 90110.
  • 26
    Wingerchuk DM, Pittock SJ, Lucchinetti CF, Lennon VA, Weinshenker BG. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology. 2007; 68: 6035.
  • 27
    Nagaishi A, Takagi M, Umemura A, Tanaka M, Kitagawa Y, Matsui M, et al.Clinical features of neuromyelitis optica in a large Japanese cohort. Comparison between phenotypes. J Neurol Neurosurg Psychiatry. 2011; 82: 13604.
  • 28
    de Seze J, Blanc F, Jeanjean L, Zéphir H, Labauge P, Bouyon M, et al. Optical coherence tomography in neuromyelitis optica. Arch Neurol. 2008; 65: 9203.
  • 29
    Naismith RT, Tutlam NT, Xu J, Klawiter EC, Shepherd J, Trinkaus K, et al. Optical coherence tomography differs in neuromyelitis optica compared with multiple sclerosis. Neurology. 2009; 72: 107782.
  • 30
    Nakamura M, Nakazawa T, Doi H, Hariya T, Omodaka K, Misu T, et al. Early high-dose intravenous methylprednisolone is effective in preserving retinal nerve fiber thichkness in patients with neuromyelitis optica. Graefes Arch Clin Exp Ophthalmol. 2010; 248: 177785.
  • 31
    Nakamura M, Miyazawa I, Fujihara K, Nakashima I, Misu T, Watanabe S, et al. Preferential spinal central gray matter involvement in neuromyelitis optica: an MRI study. J Neurol. 2008; 255: 16370.
  • 32
    Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG. Brain abnormalities in neuromyelitis optica. Arch Neurol. 2006; 63: 3906.
  • 33
    Nakashima I, Fujihara K, Miyazawa I, Misu T, Narikawa K, Nakamura M, et al. Clinical and MRI features of Japanese patients with multiple sclerosis positive for NMO-IgG. J Neurol Neurosurg Psychiatry. 2006; 77: 10735.
  • 34
    Kim W, Park MS, Lee SH, Kim SH, Jung IJ, Takahashi T, et al. Characteristic brain magnetic resonance imaging abnormalities in central nervous system aquaporin-4 autoimmunity. Mult Scler. 2010; 16: 122936.
  • 35
    Pittock SJ, Weinshenker BG, Lucchinetti CF, Wingerchuk DM, Corboy JR, Lennon VA. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol. 2006; 63: 9648.
  • 36
    Misu T, Fujihara K, Nakashima I, Sato S, Itoyama Y. Intractable hiccup and nausea with periaqueductal lesions in neuromyelitis optica. Neurology. 2005; 65: 147982.
  • 37
    Takahashi T, Miyazawa I, Misu T, Takano R, Nakashima I, Fujihara K, et al. Intractable hiccup and nausea in neuromyelitis optica with anti-aquaporin-4 antibody: a herald of acute exacerbations. J Neurol Neurosurg Psychiatry. 2008; 79: 10758.
  • 38
    Nakamura M, Misu T, Fujihara K, Miyazawa I, Nakashima I, Takahashi T, et al. Occurrence of acute large and edematous callosal lesions in neuromyelitis optica. Mult Scler. 2009; 15: 695700.
  • 39
    Baba T, Nakashima I, Kanbayashi T, Konno M, Takahashi T, Fujihara K, et al. Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody. J Neurol. 2009; 256: 2878.
  • 40
    Magaña SM, Matiello M, Pittock SJ, McKeon A, Lennon VA, Rabinstein AA, et al. Posterior reversible encephalopathy syndrome in neruomyelitis opticaspectrum disorders. Neurology. 2009; 72: 7127.
  • 41
    Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG. Revised diagnostic criteria for neuromyelitis optica. Neurology. 2006; 66: 14859.
  • 42
    Fujihara K. Neuromyelitis optica and astrocytic damage in its pathogenesis. J Neurol Sci. 2011; 306: 1837.
  • 43
    Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Clinical spectrum of CNS aquaporin-4 autoimmunity. Neurology. 2012; 78: 117985.
  • 44
    Nakamura M, Nakashima I, Sato S, Miyazawa I, Fujihara K, Itoyama Y. Clinical and laboratory features of neuromyelitis optica with oligoclonal IgG bands. Mult Scler. 2007; 13: 3325.
  • 45
    Keegan M, Pineda AA, McClelland RL, Darby CH, Rodriguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology. 2002; 58: 1436.
  • 46
    Watanabe S, Nakashima I, Misu T, Miyazawa I, Shiga Y, Fujihara K, et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler. 2007; 13: 12832.
  • 47
    Papeix C, Vidal JS, de Seze J, Pierrot-Deseilligny C, Tourbah A, Stankoff B, et al. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult Scler. 2007; 13: 2569.
  • 48
    Matsuoka T, Matsushita T, Kawano Y, Osoegawa M, Ochi H, Ishizu T, et al. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain. 2007; 130: 120623.
  • 49
    Shimizu Y, Yokoyama K, Misu T, Takahashi T, Fujihara K, Kikuchi S, et al. Development of extensive brain lesions following interferon beta therapy in relapsing neuromyelitis optica and longitudinally extensive myelitis. J Neurol. 2008; 255: 3057.
  • 50
    Tanaka M, Tanaka K, Komori M. Interferon-beta(1b) treatment in neuromyelitis optica. Eur Neurol. 2009; 62: 16770.
  • 51
    Uzawa A, Mori M, Hayakawa S, Masuda S, Kuwabara S. Different responses to interferon-beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur J Neurol. 2010; 17: 6726.
  • 52
    Palace J, Leite MI, Nairne A, Vincent A. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol. 2010; 67: 10167.
  • 53
    Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, et al. IFN-beta-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology. 2010; 75: 14237.
  • 54
    Ishizu T, Osoegawa M, Mei FJ, Kikuchi H, Tanaka M, Takakura Y, et al. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain. 2005; 128: 9881002.
  • 55
    Axtell RC, Raman C, Steinman L. Interferon-beta exacerbates Th17-mediated inflammatory disease. Trends Immunol. 2011; 32: 2727.
  • 56
    Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung HP, et al. Failure of natalizumab to present relapse in neuromuyelitis optica. Arch Neurol. 2012; 69: 23945.
  • 57
    Barnett MH, Prineas JW, Buckland ME, Parratt JD, Pollard JD. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler. 2012; 18: 10812.
  • 58
    Min JH, Kim BJ, Lee KH. Development of extensive brain lesions following fingolmod (FTY720) treatment in a patient with neuromyelitis optic spectrum disorders. Mult Scler. 2012; 18: 1135.
  • 59
    Watanabe S, Misu T, Miyazawa I, Nakashima I, Shiga Y, Fujihara K, et al. Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis. Mult Scler. 2007; 13: 96874.
  • 60
    Costanzi C, Matiello M, Lucchinetti CF, Weinshenker BG, Pittock SJ, Mandrekar J, et al. Azathioprine: tolerability, efficacy, and predictor of benefit in neuromyelitis optica. Neurology. 2011; 77: 65966.
  • 61
    Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti C, Shuster E, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol. 2009; 66: 112833.
  • 62
    Weinstock-Guttman B, Ramanathan M, Lincoff N, Napoli SQ, Sharma J, Feichter J, et al. Study of mitoxantrone for the treatment of recurrent neuromyelitis optica (Devic disease). Arch Neurol. 2006; 63: 95763.
  • 63
    Kim SH, Kim W, Park MS, Sohn EH, Li XF, Kim HJ. Efficacy and safety of mithoxantrone in patients with highly relapsing neuromyelitis optica. Arch Neurol. 2011; 68: 4739.
  • 64
    Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol. 2008; 65: 14438.
  • 65
    Kim SH, Kim W, Li XF, Jung IJ, Kim HJ. Repeated treatment with rituximab based on the assessment of peripheral circulating B cells in patients with relapsing neuromyeltis optica. Arch Neurol. 2011; 68: 141220.
  • 66
    Miyamoto K, Kusunoki S. Intermittent plasmapheresis prevents recurrence in neuromyelitis optica. Ther Apher Dial. 2009; 13: 5058.
  • 67
    Lucchinetti CF, Mandler RN, McGavern D, Bruck W, Gleich G, Ransohoff RM, et al. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain. 2002; 1(25): 145061.
  • 68
    Misu T, Fujihara K, Nakamura M, Murakami K, Endo M, Konno H, et al. Loss of aquaporin-4 in active perivascular lesions in neuromyelitis optica: a case report. Tohoku J Exp Med. 2006; 209: 26975.
  • 69
    Sinclair C, Kirk J, Herron B, Fitzgerald U, McQuaid S. Absence of aquaporin-4 expression in lesions of neuromyelitis opticabut increased expression in multiple sclerosis lesions and norma-appearing white matter. Acta Neuropathol. 2007; 113: 18794.
  • 70
    Roemer SF, Parisi JE, Lennon VA, Benarroch EE, Lassmann H, Bruck W, et al. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain. 2007; 130: 1194205.
  • 71
    Misu T, Fujihara K, Kakita A, Konno H, Nakamura M, Watanabe S, et al. Loss of aquaporin-4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain. 2007; 130: 122434.
  • 72
    Popescu BF, Lennon VA, Parisi JE, Howe CL, Weigand SD, Cabrera-Gómez JA, et al. Neuromyelitis optica unique area postrema lesions: nausea, vomiting and pathological implications. Neurology. 2011; 76: 122937.
  • 73
    Sharma R, Fischer MT, Bauer J, Felts PA, Smith KJ, Misu T, et al. Inflammation induced by innate immunity in the central nervous system leads to primary astrocyte dysfunction followed by demyelination. Acta Neuropathol. 2010; 120: 22336.
  • 74
    Matsuoka T, Suzuki SO, Suenaga T, Iwaki T, Kira J. Reappraisal of aquaporin-4 astrocytopathy in Asian neuromyelitis optica and multiple sclerosis patients. Brain Pathol. 2011; 21: 51632.
  • 75
    Kira J. Autoimmunity in neuromyelitis optica and opticospinal multiple sclerosis: astrocytopathy as a common denominator in demyelinating disorders. J Neurol Sci. 2011; 311: 6977.
  • 76
    Takano R, Misu T, Takahashi T, Izumiyama M, Fujihara K, Itoyama Y. A prominent elevation of glial fibrillary acidic protein in the cerebrospinal fluid during relapse in neuromyelitis optica. Tohoku J Exp Med. 2008; 215: 559.
  • 77
    Misu T, Takano R, Fujihara K, Takahashi T, Sato S, Itoyama Y. Marked Increase of CSF GFAP in neuromyelitis optica–an astrocytic damage marker. J Neurol Neurosurg Psychiatry. 2009; 80: 5757.
  • 78
    Takano R, Misu T, Takahashi T, Sato S, Fujihara K, Itoyama Y. Astrocytic damage is far more severe than demyelination in NMO: a clinical CSF biomarker study. Neurology. 2010; 75: 20816.
  • 79
    Petzold A, Marignier R, Verbeek MM, Confavreux C. Glial but not axonal protein biomarkers as a new supportive diagnostic criteria for Devic's neuromyelitis optica? Preliminary results on 188 patients with different neurological diseases. J Neurol Neurosurg Psychiatry. 2011; 82: 4679.
  • 80
    Uzawa A, Mori M, Arai K, Sato Y, Hayakawa S, Masuda S, et al. Cytokine and chemokien profiles in neuromyelitis optica: significance of interleukin-6. Mult Scler. 2010; 16: 144352.
  • 81
    Kaplin AI, Deshpande DM, Scott E, Krishnan C, Carmen JS, Shats I, et al. IL-6 induces regionally selective spinal cord injury in patients with the neuroinflammatory disorder transverse myelitis. J Clin Invest. 2005; 115: 273141.
  • 82
    Chihara N, Aranami T, Sato W, Miyazaki Y, Miyake S, Okamoto T, et al. Interleukin6 signaling promotes anti-aquaporin 4 antibody production from plasmablasts in neuromyelitis optica. Proc Natl Acad Sci U S A. 2011; 108: 37016.
  • 83
    Fujii C, Tokuda T, Ishigami N, Mizuno T, Nakagawa M. Usefulness of serum S100 B as a marker for the acute phase of aquaporin-4 autoimmune syndrome. Neurosci Lett. 2011; 494: 868.
  • 84
    Storoni M, Verbeek MM, Illes Z, Marignier R, Teunissen CE, Grabowska M, et al. Serum GFAPlevels in optic neuropathies. J Neurol Sci. 2012; 317: 11722.
  • 85
    Hinson SR, Pittock SJ, Lucchinetti CF, Roemer SF, Fryer JP, Kryzer TJ, et al. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology. 2007; 69: 222131.
  • 86
    Vincent T, Saikali P, Cayrol R, Roth AD, Bar-Or A, Prat A, et al. Functional consequences of neuromyelitis optica-IgG astrocyte interactions on blood-brain barrier permeability and granulocyte recruitment. J Immunol. 2008; 181: 57307.
  • 87
    Kinoshita M, Nakatsuji Y, Moriya M, Okuno T, Kumanogoh A, Nakano M, et al. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. NeuroReport. 2009; 20: 50812.
  • 88
    Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, et al. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem Biophys Res Commun. 2009; 386: 6237.
  • 89
    Bennett JL, Lam C, Kalluri SR, Saikali P, Bautista K, Dupree C, et al. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann Neurol. 2009; 66: 61729.
  • 90
    Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, et al. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol. 2009; 66: 63043.
  • 91
    Saadoun S, Waters P, Bell BA, Vincent A, Verkman AS, Papadopoulos MC. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain. 2010; 133: 34961.
  • 92
    Saadoun S, Waters P, Macdonald C, Bridges LR, Bell BA, Vincent A, et al. T cell deficiency does not reduce lesions in mice produced by intracerebral injection of NMO-IgG and complement. J Neuroimmunol. 2011; 235: 2732.
  • 93
    Kinoshita M, Nakatsuji Y, Kimura T, Moriya M, Takata K, Okuno T, et al. Anti-aquaporin-4 antibody induces astrocytic cytotoxicity in the absence of CNS antigen-specific T cells. Biochem Biophys Res Commun. 2010; 394: 20510.
  • 94
    Nishiyama S, Ito T, Misu T, Takahashi T, Kikuchi A, Suzuki N, et al. A case of NMO seropositive for aquaporin-4-antibody over 10 years before the onset. Neurology. 2009; 72: 19601.
  • 95
    Pisani F, Mastrototaro M, Rossi A, Nicchia GP, Tortorella C, Ruggieri M, et al. Identification of two major conformational aquaporin-4 epitopes for neuromyelitis optica autoantibody binding. J Biol Chem. 2011; 286: 921624.
  • 96
    Hinson SR, Romero MF, Popescu BF, Lucchinetti CF, Fryer JP, Wolburg H, et al. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc Natl Acad Sci U S A. 2012; 109: 124550.
  • 97
    Phuan PW, Ratelade J, Rossi A, Tradtrantip L, Verkman AS. Complement-dependent cytotoxicity in neuromyelitis optica requires aquaporin-4 assembly in orthogonal arrays. J Biol Chem. 2012; 287: 1382939.
  • 98
    Tradtrantip L, Zhang H, Saadoun S, Phuan PW, Lam C, Papadopoulos MC, et al. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann Neurol. 2012; 71: 31422.
  • 99
    Marignier R, Nicolle A, Watrin C, Touret M, Cavagna S, Varrin-Doyer M, et al. Oligodendrocytes are damaged by neuromyelitis opticda immunoglobulin G via astrocytic injury. Brain. 2010; 133: 257891.
  • 100
    Hinson SR, Roemer SF, Lucchinetti CF, Fryer JP, Kryzer TJ, Chamberlain JL, et al. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair gulutamate transport by down-regualting EAAT2. J Exp Med. 2008; 205: 247381.
  • 101
    Ratelade J, Bennett JL, Verkman AS. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J Biol Chem. 2011; 286(52): 4515664.
  • 102
    Matsuya N, Komori M, Nomura K, Nakane S, Fukudome T, Goto H, et al. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int Immunol. 2011; 23: 56573.
  • 103
    Pohl M, Fischer MT, Mader S, Schanda K, Kitic M, Sharma R, et al. Pathogenic T cell responses against aquaporin 4. Acta Neuropathol. 2011; 122: 2134.
  • 104
    Saadoun S, Waters P, Macdonald C, Bell BA, Vincent A, Verkman AS, et al. Neutrophil protease inhibition reduces neuromylitis optica-immunoglobulin G-induced damage in mouse brain. Ann Neurol. 2012; 71: 32333.
  • 105
    Jacob A, Saadoun S, Kitley J, Leite M, Palace J, Schon F, et al. Detrimental role of granulocyte-colony stimulating factor in neuromyelitis optica: clinical case and histological evidence. Mult Scler. 2012; [Epub ahead of print].
  • 106
    Shimizu F, Sano Y, Takahashi T, Haruki H, Saito K, Koga M, et al. Sera from neuromyelitis optica patients disrupt the blood-brain barrier. J Neurol Neurosurg Psychiatry. 2012; 83: 28897.
  • 107
    McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001; 50: 1217.
  • 108
    Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69: 292302.
  • 109
    Sato D, Fujihara K. NMO without typical opticospinal phenotype. Mult Scler. 2010; 16: 11545.